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Abstract To directly define the role of phospholipase CQ1
(PLCQ1) in NF-UB activation, NF-UB promoted luciferase
reporter gene plasmid (pNF-UB-Luc) was transfected into rat-
3Y1 fibroblasts that overexpress whole PLCQ1 (PLCQ1-3Y1), src
homology domains SH2-SH2-SH3 of PLCQ1 (SH223-3Y1) and
v-src (Src-3Y1). Transient transfection with pNF-UB-Luc
remarkably increased the luciferase activity in all three
transformants compared with normal rat-3Y1 cells. Pretreat-
ment with inhibitors of protein tyrosine kinase reduced this
increase in luciferase activity, but U73122 (a PLC inhibitor) did
not. While PD98059, an inhibitor of mitogen activated protein
kinase (MAPK), significantly reduced the luciferase activity,
there was no effect by wortmannin and Ro-31-8220, inhibitors of
phosphatidylinositol 3-kinase (PI3K) and protein kinase C
(PKC), respectively. This study shows a direct evidence that
the SH2-SH2-SH3 region of PLCQ1 contributes to the NF-UB
signaling and that MAPK, but not PI3K and PKC, is involved in
SH2-SH2-SH3 mediated NF-UB activation in these cells.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
The REL/NF-UB/IU-B superfamily of signal transducers
and transcription factors are paradigmatic of molecular mech-
anisms by which rapid responses in the immune system, cell
proliferation and apoptosis, can be achieved [1^3]. A large
number of stimuli, bacterial lipopolysaccharide, UV irradia-
tion and reactive oxygen intermediates, can activate the NF-
UB/REL signaling pathways [1,4,5]. In regulation of NF-UB
signaling, in Jurkat T cells, the regulatory subunit p85 of
phosphatidylinositol 3-kinase (PI3K) has been shown to asso-
ciate with the Tyr-42 residue on the IU-BK, releasing NF-UB
for its translocation [6]. Moreover, c-src was implicated in the
tyrosine phosphorylation of IU-BK in bone marrow macro-
phages [7]. Bacterial phospholipase C (PLC) was also reported
to induce NF-UB activation [8].
Phospholipase CQ1 (PLCQ1), one member of the PLC iso-
zyme family, catalyzes the hydrolysis of phosphatidylinositol
4,5-bisphosphate (PIP2), creating inositol 1,4,5-trisphosphate
(IP3) and diacylglycerol (DAG). These second messengers
stimulate the release of Ca2 from an internal store and acti-
vate protein kinase C (PKC), respectively [9], ultimately lead-
ing to many biological processes. PLCQ1 contains two src
homology domains 2 (SH2) and one src homology domain
3 (SH3), needed for e¡ector activation or protein^protein in-
teractions [10]. Rat-3Y1 cells overexpressing PLCQ1 (PLCQ1-
3Y1) or SH2-SH2-SH3 domain of PLCQ1 (SH223-3Y1) exhib-
ited morphological change to transformed cells and induced
tumors when injected into nude mice [11]. Furthermore, treat-
ment of CHO-K1 cells with lipopolysaccharide (LPS), DAG
or bacterial PLC induced NF-UB activation [8] and there also
were reports on the involvement of phosphatidylcholine spe-
ci¢c PLC (PC-PLC) in NF-UB activation [12,13]. These results
suggest the possible involvement of PLCQ1 in the activation of
NF-UB signaling. However, there has been no direct evidence
for the PLC involvement in the activation of NF-UB.
In this study, using the PLCQ1-3Y1, SH223-3Y1 and Src-
3Y1 cells, we showed that SH2-SH2-SH3 domain of PLCQ1 is
responsible for its e¡ect on NF-UB signaling.
2. Materials and methods
2.1. Materials
Wortmannin, Ro-31-8220, PD98059, U73122 and tyrphostin A25
were purchased from Calbiochem, genistein and poly(dI-dC) were
obtained from Sigma, Sephadex G-50, T4 polynucleotide kinase
(T4PNK) and luciferase reporter gene assay kit (constant light signal)
were from Boehringer Mannheim and lipofectamine was purchased
from Gibco-BRL.
2.2. Plasmids and oligonucleotides
Plasmids pCRE-Luc, pNF-UB-Luc, pAP1-Luc, and pFC-MEKK
were from Stratagene. These inducible vectors (5.7 kb) contain the
luciferase reporter gene driven by a basic promoter element (TATA
box) plus a de¢ned inducible cis-enhancer element. Expression of the
Photinus pyralis (¢re£y) luciferase gene in the reporter plasmid is
controlled by a synthetic promoter that contains tandem repeats of
cyclic AMP response element (CRE, 4UAGCCTGACGTCAGAG),
and the binding sites for nuclear factor UB (NF-UB, 7UTGACTAA)
and activator protein 1 (AP-1, 5UTGGGGACTTTCCGC). Constitu-
tive expression of MEK kinase (MEKK) was driven by CMV pro-
moter. Transcription consensus NF-UB, AP-1 and CREB oligonucleo-
tides were obtained from Promega (Cat# E3291, E3201 and E3281,
respectively).
2.3. Cell culture
PLCQ1-3Y1 and SH223-3Y1 were cultured in Dulbecco’s modi¢ed
Eagle’s medium (DMEM) containing an appropriate amount of hy-
gromycin B supplemented with 10% of fetal bovine serum (FBS). Rat-
3Y1 and Src-3Y1 cells were maintained in DMEM with 10% of FBS
[11].
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2.4. Transfection of cells with pNF-UB-Luc, pAP1-Luc and pCRE-Luc
All procedures for the transfection were undertaken by slight mod-
i¢cation of the liposome transfection method prescribed by the sup-
pliers. Cells were seeded at a density of 1.5U103 cells/ml per well in
DMEM supplemented with 10% fetal bovine serum in a 12-well plate
and grown overnight in a humidi¢ed CO2 incubator at 37‡C. After
washing with phosphate bu¡ered saline (PBS), cells were loaded with
100 Wl of liposomal DNA mixture and 400 Wl of serum-free OPTI-
MEM at 37‡C for 24 h. For preparation of the liposomal DNA
mixture, 2.5 Wl of lipofectamine, 0.5 Wg of reporter vectors and an
appropriate amount of pFC-MEKK were mixed in 100 Wl of serum-
free OPTI-MEM for 45 min at room temperature. Meanwhile, test
compounds (wortmannin, Ro-31-8220, U73122, tyrphostin A25 and
genistein) were treated to the cells throughout the experiments for
24 h.
2.5. Determination of luciferase activity
After transfection for 24 h, cells were washed with PBS to remove
the phenol red in the medium and refreshed with 100 Wl of PBS. Cells
were lysed by adding 100 Wl of lysis solution of luciferase assay kit and
the supernatants were counted by luminometer for luciferase activity
expressed as relative light units (RLU).
2.6. Electrophoretic mobility shift assay (EMSA)
EMSA was done according to the procedure of Janssen and Sen
[14]. Brie£y, cells (2^10U106) grown in complete medium were lysed
on ice for 15 min in hypotonic bu¡er containing 10 mM HEPES (pH
7.8), 10 mM KCl, 2 mM MgCl2, 0.1 mM ethylenediaminetetraacetic
acid (EDTA, sodium salt), 0.2 mM NaF, 0.2 mM Na3VO4, 0.4 mM
phenylmethylsulfonyl £uoride (PMSF), 0.3 mg/ml leupeptin, 1 mM
dithiothreitol (DTT) and 0.6% Nonidet P-40. After centrifugation at
16 000Ug for 1 min, the pellet of nuclei was resuspended in ice-cold
high salt extraction bu¡er (50 mM HEPES (pH 7.8), 50 mM KCl,
300 mM NaCl, 0.1 mM EDTA, 0.2 mM NaF, 0.2 mM Na3VO4,
0.4 mM PMSF, and DTT) for 30 min at 4‡C. The nuclear lysates
were then centrifuged at 16 000Ug for 15 min at 4‡C, and the super-
natant was stored at 380‡C or further proceeded for EMSA. NF-UB
oligonucleotide (3.5 pmol) was incubated with 50 WCi [Q-32P]ATP in
the presence of 5 U T4 polynucleotide kinase and 1Ukinase bu¡er
supplied with the kinase (Boehringer) at 37‡C for 30 min. The reac-
tion was stopped by 50 mM EDTA, centrifuged through a Sephadex
G-50 column to remove unincorporated 32P, and stored at 320‡C
until use. For the DNA binding reaction and electrophoresis, nuclear
protein extract (5 Wg) was incubated in the presence of 0.03 pmol
32P-endlabeled NF-UB oligonucleotide, 40 mM HEPES (pH 7.8),
10% (v/v) glycerol, 1 mM MgCl2, 0.1 mM DTT, and 500 ng poly-
(dI-dC) (Sigma) in a ¢nal volume of 10 Wl for 20 min at room temper-
ature. Following incubation, the sample was loaded on a 6% non-
denaturing polyacrylamide gel in 0.5UTris/boric acid/EDTA (TBE)
bu¡er and gels were autoradiographed for band shift examination.
2.7. Measurement of total inositol phosphates (IPt)
Cells were fasted in inositol-free DMEM containing 1 WCi/ml of
myo-[2-3H]inositol for 24 h. Cells were rinsed twice and incubated
in inositol-free DMEM containing 20 mM HEPES, pH 7.5, 20 mM
LiCl and 1 mg/ml BSA at 37‡C for 15 min. U73122 and wortmannin
were treated to the cells for 15 min prior to stimulation with serum
(10%) for further 30 min and the incubation was stopped by adding
ice-cold 5% HClO4. Inositol phosphates were extracted for 30 min on
ice and the acid soluble fraction applied to a Bio-Rad AG 1-X8 anion
exchange column. Inositol phosphates were eluted with varying con-
centrations of ammonium formate as previously described [15].
3. Results
It was previously shown that overexpression of PLCQ1 in
NIH 3T3 (NIH 3T3Q1) cells enhanced the platelet derived
growth factor (PDGF) induced phosphoinositide hydrolysis
Fig. 1. E¡ect of PLCQ1, SH2-SH3 and v-src on NF-UB promoter
activity. NIH 3T3 and NIH 3T3Q1 (A) or rat-3Y1, PLCQ1-3Y1 and
SH223-3Y1 (B) cells, at a density of 1U103 cells/ml in a 12-well
plate, were cultured for 24 h and thereafter transiently transfected
with 1 Wg of pNF-UB-Luc, pAP1-Luc and pCRE-Luc in OPTI-
MEMI at 37‡C for 24 h. The luciferase activity was measured using
the constant light signal luciferase assay kit as described in Section
2. Each bar shows a representative from triplicate experiments.
Table 1
E¡ect of inhibitors of PLC (U73122) and PTK (tyrphostin A25) on inositol phosphate formation and NF-UB promoter directed luciferase activ-
ity in NIH 3T3 and rat-3Y1 cells
Inhibitor Inositol phosphates (IPt) Luciferase
NIH 3T3Q1 PLCQ1-3Y1 Rat-3Y1 PLCQ1-3Y1 SH223-3Y1 Src-3Y1
U73122 12 þ 2a 30 þ 5 85 þ 3 85 þ 5 85 þ 3 92 þ 4
Tyrphostin A25 6 þ 1 21 þ 3 62 þ 4 41 þ 3 20 þ 3 35 þ 5
After semicon£uent growth, cells were labeled with 1 WCi/ml of myo-[2-3H]inositol in inositol-free DMEM for 24 h, washed once with phos-
phate bu¡ered saline and pretreated with U73122 (3 WM) or tyrphostin A25 (5 WM) for 15 min before serum stimulation for 30 min. The
amount of intracellular inositol phosphate was measured as described in Section 2. On the other hand, cells were transfected with 1 Wg of
pNF-UB-Luc plasmid in OPTI-MEMI medium in the presence or absence of U73122 (3 WM) or tyrphostin A25 (5 WM) for 24 h and the lucifer-
ase activity was measured as in Fig. 1.
aAll the values were expressed as a percentage to control values without the inhibitors and as means þ S.D. from a representative of triplicate
experiments.
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and phospholipase D (PLD) activities [16^18]. In addition, the
SH2-SH3 domain of PLCQ1 as well as PLCQ1 itself caused
tumorigenic growth of the transfected rat-3Y1 cells [11]. To
see if PLCQ1 a¡ect the NF-UB activation, NIH 3T3 and NIH
3T3Q1 cells were transiently transfected with pNF-UB-Luc
containing the NF-UB promoter element and luciferase report-
er gene (Fig. 1A). There was a remarkable increase in the
amount of luciferase activity in NIH 3T3Q1 cells compared
to NIH 3T3 cells. This was the same in rat-3Y1 ¢broblasts
(Fig. 1B). PLCQ1-3Y1, SH223-3Y1 and Src-3Y1 all showed
greatly higher levels of luciferase activity than in rat-3Y1 cells
when transfected with pNF-UB-Luc plasmid. However, the
increase was not signi¢cant when transfected with pAP1-Luc
and pCRE-Luc in all the transformed cells.
The results of luciferase reporter gene assay were consistent
with those of gel mobility shift assay in Fig. 2. All three rat-
3Y1 transformants showed a remarkable increase in NF-UB
binding to its consensus oligonucleotide compared to normal
rat-3Y1 cells (Fig. 2A). The binding speci¢city of NF-UB was
con¢rmed by the observation that there was complete inhibi-
tion of NF-UB binding by 10-fold molar excess of unlabeled
NF-UB but not by AP-1 and CRE consensus oligonucleotides
in all the cells (Fig. 2B). To see if PLC is involved in the NF-
UB activation process, U73122, an inhibitor of PLC [19,20],
was treated to the rat cells together with the pNF-UB-Luc
plasmid (Table 1). Unexpectedly, U73122 had only a negli-
gible e¡ect on luciferase activity while it reduced serum in-
duced inositol phosphate formation by PLC in both NIH
3T3Q1 and PLCQ1-3Y1 cells. However, there was a signi¢cant
reduction in luciferase activity by tyrphostin A25, an inhibitor
of protein tyrosine kinase [21] in all the cell types. This in-
dicates that PLCQ1 enzyme activity itself is not crucial but
SH2-SH3 domain of PLCQ1 is important for NF-UB activa-
tion possibly through the src homology mediated protein^pro-
tein interaction or protein tyrosine phosphorylations.
It was then necessary to determine what proteins or en-
zymes are involved in NF-UB signaling. PI3K was reported
Fig. 2. Retardation of NF-UB oligonucleotide electrophoretic mobi-
lity by PLCQ1, SH2-SH2-SH3 domain, and v-src. A: Following lysis
of con£uent growth of cells, nuclear proteins (5 Wg) were incubated
with 32P-labeled NF-UB consensus oligonucleotide (0.03 pmol,
100 000 WCi) for 20 min at room temperature and the reaction mix-
tures were applied to a 6% non-denaturing acrylamide gel. (3) indi-
cates reaction without nuclear lysate. B: Reactions were performed
in the absence (3) or presence of unlabeled consensus oligonucleo-
tides NF-UB (N), AP-1 (A) and CRE (C) showing the speci¢city of
NF-UB binding.
Fig. 3. E¡ect of inhibitors of PI3K, PKC, PTK and MAPK on
NF-UB promoter activity. A: Just prior to pNF-UB-Luc transfection
(1 Wg), cells were treated with the inhibitors: wortmannin (2 WM),
Ro-31-8220 (2 WM) and genistein (100 WM). B: Cells were cotrans-
fected with pNF-UB-Luc (1 Wg) and pFC-MEKK (50 ng) in the
presence or absence of PD98059 (4 WM). All the other procedures
were the same as in Fig. 1. In panel B, the control values at 100%
for rat-3Y1, PLCQ1-3Y1 and SH223-3Y1 were 920 RLU, 30 000
RLU, and 26 000 RLU, respectively. Each bar shows a representa-
tive from triplicate experiments.
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to associate with IU-BK in a cell type speci¢c manner [6,7] and
PKC isoforms have also been implicated in NF-UB activation
[12]. To examine the involvement of these enzymes in NF-UB
signaling, wortmannin, Ro-31-8220 and genistein, inhibitors
of PI3K, PKC and protein tyrosine kinase (PTK), respec-
tively, were treated to the cells (Fig. 3A). It was observed
that while genistein signi¢cantly reduced the luciferase activ-
ity, wortmannin (IC50, 5 nM) and Ro-31-8220 (IC50, 200 nM)
had no e¡ect even at concentrations of 2 WM.
It was reported that NF-UB can be activated by TRAF2
mediated MAP3K [22]. To test MAPK involvement in rat-
3Y1 cells, cells were treated with PD98059, an inhibitor of
MAPK pathway, or transfected with a MEKK containing
plasmid, pFC-MEKK. As shown in Fig. 3B, MEKK in-
creased NF-UB activation in all transfectants and the increase
was much more pronounced in PLCQ1-3Y1 and SH223-3Y1
than in rat-3Y1 cells. On the contrary, as expected, PD98059
reduced the NF-UB mediated luciferase activity in all but rat-
3Y1 cells.
4. Discussion
Although there have been reports for the agonist induced
activation of PLCQ1 and NF-UB, direct evidence for the
PLCQ1 mediated NF-UB activation has not been reported as
yet. Some of the observations at best were with bacterial PLC
or phosphatidylcholine speci¢c PLC (PC-PLC) [8,12,13]. In
this study, we used stable transfectants with mammalian phos-
phoinositide speci¢c PLC (PI-PLC). NIH 3T3Q1 cells showed
a higher level of phosphoinositide hydrolysis than NIH 3T3
cells in response to PDGF stimulation. However, without ag-
onist, PLCQ1 was not activated in either the NIH 3T3 or NIH
3T3Q1 cells (data not shown) [16^18]. Regarding the NF-UB
activation, however, NIH 3T3Q1 cells showed much higher
level of NF-UB activity compared to NIH 3T3 cells even in
serum-free state (Fig. 1A). This means that PLCQ1 activity is
not relevant to NF-UB activation, which is further con¢rmed
in Fig. 1B and Table 1 in which not only PLCQ1 itself but also
the src homology domains of PLCQ1 greatly increased the
NF-UB promoted luciferase activity. Furthermore, a PLC in-
hibitor U73122 did not a¡ect the NF-UB activation. Thus, the
SH2-SH2-SH3 domain in PLCQ1 appears to mediate the NF-
UB activation. The contribution of the src homology domains
to NF-UB activation was further supported in that v-src trans-
formed Src-3Y1 cells also showed elevated level of luciferase
activity and gel mobility shift (Figs. 1B and 2).
In regards to PI3K and PKC, wortmannin and Ro-31-8220
were treated to the rat cells. PI3K was known to bind to
tyrosine phosphorylated IU-BK and wortmannin inhibited
this interaction in pervanadate stimulated Jurkat T cells [6].
However, we did not notice any inhibition of NF-UB pro-
moted luciferase activity even at high concentrations of wort-
mannin. PKC-j was shown to phosphorylate IU-BK in vitro
[23], and in vivo studies with constitutively active isoforms
demonstrated novel PKC-O to be a potent inducer of a NF-
UB dependent reporter gene [24]. In this study, however, treat-
ment of a PKC inhibitor, Ro-31-8220, did not reduce NF-UB
activity (Fig. 3A), and we also had the same result with cal-
phostin C (data not shown). Thus, it is possible that active
forms of PKC isozymes in quiescent rat-3Y1 cells could be
PKC-j and V since atypical PKC-j and V are independent of
Ca2 and DAG for their enzyme activities and do not induce
IU-BK phosphorylation [25]. Another possibility could be
raised but these assumptions should be exploited in a further
study.
MAPK is another Ser/Thr kinase involved in NF-UB acti-
vation, although bifurcation of NF-UB and c-Jun N-terminal
kinase (JNK/SAPK) pathways at TRAF2 was reported pre-
viously [22]. From the results in Fig. 3B, it appears that the
SH2-SH2-SH3 domain of PLCQ1 makes the cells more suscep-
tible to MAPK activity. This can be supported by the obser-
vation that an MEK inhibitor PD98059 reduced NF-UB ac-
tivity in both PLCQ1-3Y1 and SH223-3Y1 cells but not in rat-
3Y1 cells. Hence, MAPK seems to be directly or indirectly
associated with PLCQ1.
Recently, it was reported that an SH3 containing rac target
POSH leads to the nuclear translocation of NF-UB [26]. Be-
sides, Fyn was found to activate NF-UB signaling through its
intact SH2 domain [27], implying the involvement of src ho-
mology domains in NF-UB signaling pathway. In this study,
however, we clearly demonstrate that PLCQ1 can mediate the
NF-UB activation but the SH2-SH2-SH3 domain of the en-
zyme is responsible for NF-UB activation, and that PTK(s)
and MAPK but not PI3K and PKC are involved directly or
indirectly in this process.
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